Latest news with #PfizerInc
Yahoo
5 hours ago
- Business
- Yahoo
Pfizer Stock: Analyst Estimates & Ratings
With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New York City. Founded in 1849, Pfizer discovers, develops and manufactures medicines and vaccines across a broad range of therapeutic areas, including oncology, immunology, rare diseases, cardiology, endocrinology and vaccines. Shares of this pharmaceutical giant have underperformed the broader market over the past year. PFE has declined 21% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 17.1%. In 2025, PFE stock is down 8.4%, compared to SPX's 8.6% rise on a YTD basis. More News from Barchart Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Dear Microsoft Stock Fans, Mark Your Calendars for Aug. 1 Is Lucid Motors Stock a Buy, Sell, or Hold for July 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in, PFE has also trailed the Invesco Pharmaceuticals ETF (PJP), which has fallen 2.7% over the past year and has surged 1.3% in 2025 On July 24, Pfizer announced a global (excluding China) licensing agreement with 3SBio for exclusive rights to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. The deal strengthens Pfizer's oncology pipeline and reinforces its position in innovative cancer research. However, its shares dropped 2.2% in the next trading session amid macroeconomic headwinds. For the current fiscal year, ending in December, analysts expect PFE's EPS to decline 1.3% year over year to $3.07 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 22 analysts covering PFE stock, the consensus is a 'Moderate Buy.' That's based on six 'Strong Buy' ratings, one 'Moderate Buy,' 14 'Holds,' and one 'Strong Sell.' This configuration is less bullish than three months ago, when seven analysts suggested a 'Strong Buy.' On April 30, UBS Group AG (UBS) analyst Trung Huynh raised Pfizer's price target from $24 to $25 while maintaining a 'Neutral' rating. Despite mixed revenue performance, the analyst highlighted Pfizer's significant cost savings as a positive factor. The mean price target of $27.81 represents a 14.4% premium to PFE's current price levels. The Street-high price target of $33 suggests an ambitious upside potential of 35.7%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
4 days ago
- Business
- Globe and Mail
Pfizer's PAXLOVID Study: Real-World Insights on COVID-19 Treatment
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting a study titled 'Post Marketing Surveillance to Observe Safety and Effectiveness of PAXLOVID in Patients With Positive Results of Viral Testing, and Who Are at High Risk for Progression to Severe COVID-19.' The study aims to assess the real-world safety and effectiveness of PAXLOVID in patients at high risk of severe COVID-19, particularly in Korea. This is significant as it provides insights into the drug's performance outside controlled clinical settings. The intervention being tested is PAXLOVID, an antiviral treatment intended to reduce the severity of COVID-19 in high-risk patients. The study focuses on patients who have tested positive for the virus and are at risk of severe outcomes, including hospitalization or death. This observational study follows a case-only model and does not involve any specific allocation or masking. The primary purpose is to gather real-world data on PAXLOVID's effectiveness and safety over a 28-day follow-up period after treatment. The study began on November 29, 2023, with its primary completion and estimated study completion dates yet to be announced. The last update was submitted on July 22, 2025, highlighting ongoing data collection and analysis. Market implications of this study are significant for Pfizer's stock performance as positive real-world data could bolster investor confidence and market position against competitors. The study's outcomes may influence healthcare providers' decisions and potentially increase PAXLOVID's market share. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Japan Today
16-07-2025
- Health
- Japan Today
Japan discards state-acquired COVID-19 drugs worth ¥240 billion
The government discarded COVID-19 oral medicines believed to be worth around 240 billion yen in the fiscal year through March as they had passed their expiry dates, health ministry officials said Wednesday. While the exact purchase price remains unclear, the value was calculated in accordance with current prices. The amount is enough to treat some 2.5 million people. The government acquired the oral drugs at the height of the coronavirus pandemic and provided them free of charge to hospitals and clinics nationwide. But many of them were unused after COVID-19 was downgraded to the same category as seasonal influenza in May 2023, which required people to pay for COVID-19 treatment. Drugmakers had also started general distribution of COVID-19 medicine in Japan themselves. A Ministry of Health, Labor and Welfare official said offering the drugs to other countries was considered but legally difficult. Among the 2 million doses of Pfizer Inc's nirmatrelvir and 1.6 million doses of Merck & Co's molnupiravir procured by the government, about 1.75 million doses of nirmatrelvir and some 780,000 doses of molnupiravir were disposed of, according to the ministry. The government also secured 2 million doses of Shionogi & Co's ensitrelvir but about 1.77 million of them are unused, the ministry said. They are expected to be discarded after they reach their expiration dates starting next fiscal year. © KYODO
Mint
16-07-2025
- Business
- Mint
Zohran Mamdani backs away from ‘globalize the intifada' slogan, reaffirms tax plan for NYC's wealthy
New York City mayoral candidate Zohran Mamdani told a group of prominent business leaders on Tuesday (July 15) that he would begin discouraging the use of the phrase 'globalize the intifada,' according to a report by Bloomberg, which cited people with knowledge of the meeting. The shift came after a pointed question from Pfizer Inc. CEO Albert Bourla, who moderated the meeting and personally raised concerns about the slogan, widely used in anti-Israel demonstrations. Bourla, who lost family members in the Holocaust and helped deliver Pfizer's COVID-19 vaccine to Israel in 2020 through an agreement with then-Prime Minister Benjamin Netanyahu, moderated the closed-door session. Mamdani, a 33-year-old democratic socialist, had been a long-time Palestinian rights activist, and the phrase 'globalize the intifada' is used in reference with the violent Palestinian uprisings against Israel. As per the news report, Mamdani 'appeared to relent', and committed to discouraging the slogan going forward, signaling his willingness to recalibrate some of his more contentious positions as he courts mainstream support. The meeting was held with about 100 members of the Partnership for New York City, a powerful coalition that includes executives from top banks, law firms, real estate developers, and media companies. The event marked part of Mamdani's broader effort this week to engage with the business community, following his upset victory over former Governor Andrew Cuomo in the Democratic primary. Mamdani's mayoral campaign centered on pledges to freeze rents on affordable housing and finance free bus services and government-run grocery stores by imposing new taxes on corporations and high-income earners. However, on other issues, the Queens assemblyman remained steadfast, reaffirming his goals and dismissing concerns over higher taxes, reportedly stating that wealthy New Yorkers would not leave the city because of them. On policing, Mamdani told the group he would consider retaining current NYPD Commissioner Jessica Tisch but stopped short of any commitments. Tisch's father, James Tisch, chairman of Loews Corp., was in attendance. Executives present included Uber CEO Dara Khosrowshahi, Hearst CEO Steve Swartz, Related Companies CEO Jeff Blau, and Centerview Partners co-founder Blair Effron, Bloomberg reported. Mamdani campaign spokesperson Jeffrey Lerner said the meeting was 'a constructive, honest discussion,' and added, 'Zohran continues to believe that working in partnership is the best way to deliver an affordable city for all New Yorkers.' During the meeting, Mamdani also said he would examine the city's Department of Education for inefficiencies and explore leveraging the upcoming FIFA World Cup to bolster New York's infrastructure, according to Bloomberg. Mamdani's meetings with business leaders come as he attempts to consolidate broader support in what could be a more competitive general election than usual for deep-blue New York City. He will face incumbent Mayor Eric Adams, Andrew Cuomo (running as an independent), Republican Curtis Sliwa, and attorney Jim Walden, also running as an independent.
Yahoo
16-07-2025
- Business
- Yahoo
Mamdani Talks ‘Intifada', Taxes in Grilling by Business Leaders
(Bloomberg) -- New York City mayoral candidate Zohran Mamdani told business leaders that he would begin to discourage the use of the phrase 'globalize the intifada' after being pressed on his views by Pfizer Inc. Chief Executive Officer Albert Bourla, according to people with knowledge of the matter. The Dutch Intersection Is Coming to Save Your Life Advocates Fear US Agents Are Using 'Wellness Checks' on Children as a Prelude to Arrests LA Homelessness Drops for Second Year Manhattan, Chicago Murder Rates Drop in 2025, Officials Say Mamdani, the 33-year-old democratic socialist who shocked New York City's business and political establishment by beating Andrew Cuomo in last month's Democratic mayoral primary, met Tuesday with about 100 business leaders from the Partnership for New York City. The group is a 350-member coalition of the city's largest banks and media companies as well as investment, real estate and law firms. The meeting, which came at Mamdani's request, is one of several scheduled this week between the Democratic nominee and the business community, which is grappling with the potential impact of Mamdani's leadership on the city. Mamdani campaigned on promises to freeze the rent on affordable housing, and fund free buses and government-run grocery stores with new taxes on corporations and high-earners. JPMorgan Chase & Co. CEO Jamie Dimon last week criticized Mamdani and the Democratic reaction to his election, describing him as 'more of a Marxist than a socialist.' Bourla, whose grandparents perished at Auschwitz, moderated the event. Mamdani, an activist for Palestinian causes, has been criticized for refusing to denounce calls by anti-Israel protesters to 'globalize the intifada,' a reference to the armed Palestinian uprisings against Israel. Bourla in 2020 struck an agreement with Israeli Prime Minister Benjamin Netanyahu to use Israel as a test case for Pfizer's Covid-19 vaccine. In Tuesday's meeting, Mamdani appeared to relent on the matter, the people said, saying he would discourage such language going forward. But on other subjects the Queens assemblyman held firm, reiterating his goals and brushing off concerns about higher taxes by saying wealthy New Yorkers would stay put regardless, the people said. Mamdani also said he'd consider, but wouldn't commit, to keeping Police Commissioner Jessica Tisch, the people said. Her father, Loews Corp. Chairman James Tisch, was at the meeting. Other attendees included Uber Technologies Inc. CEO Dara Khosrowshahi, Hearst Corp. CEO Steve Swartz, Related Cos CEO Jeff Blau, and Centerview Partners' co-founder Blair Effron, the people said. 'Zohran appreciated the meeting today, and felt it was a constructive, honest discussion,' Jeffrey Lerner, a spokesman for Mamdani's campaign, said in a statement. 'We look forward to the opportunity to build on this conversation, even in navigating disagreement on fiscal policy. Zohran continues to believe that working in partnership is the best way to deliver an affordable city for all New Yorkers.' Business leaders who attended the Tuesday event thought Mamdani was 'the most impressive candidate they have seen in generations,' Kathy Wylde, CEO of the coalition, said in an interview on CNBC Wednesday. But Wylde said Mamdani is 'clearly, totally inexperienced' and that she doesn't think the candidate changed the minds of city business leaders. Mamdani also told attendees he would examine the New York City Department of Education for waste and duplication, and that he would look to use the World Cup as an opportunity to build up city infrastructure. Mamdani has been making efforts to consolidate traditional institutions behind his candidacy ahead of November's mayoral race, which could prove unusually competitive in a heavily blue city where the Democratic nominee has been all but assured of victory in recent elections. He will face off against four other candidates: incumbent Mayor Eric Adams, former governor Cuomo, and attorney Jim Walden — all of whom are running as independents — as well as Republican Curtis Sliwa. President Donald Trump, who has described Mamdani as a 'communist lunatic,' said this week that Cuomo should stay in the race, even after losing by more than 12 percentage points to Mamdani in the primary. --With assistance from Aysha Diallo. (Updates with comments by Partnership for New York City CEO in 10th paragraph) Forget DOGE. Musk Is Suddenly All In on AI How Starbucks Is Engineering a Turnaround With Warm Vibes and Cold Foams How Hims Became the King of Knockoff Weight-Loss Drugs Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot The New Third Rail in Silicon Valley: Investing in Chinese AI ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
